{"name":"BlossomHill Therapeutics","slug":"blossomhill-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BH-30236","genericName":"BH-30236","slug":"bh-30236","indication":"Other","status":"phase_1"},{"name":"BH-30643","genericName":"BH-30643","slug":"bh-30643","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BH-30236","genericName":"BH-30236","slug":"bh-30236","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BH-30643","genericName":"BH-30643","slug":"bh-30643","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNXzhCWEJsY2owbGhpaEl4djZvbWU2QTV0elFrMFExc3o0V2FkXzhRV2VIRlZtdDBMYTVpNVFlVXVscGdMNFV0eTVNUjFIVmlxLWF6ZXB2dHUyUHpwVmZUMThwRHJ5TDZPRklIVTVsc0JvNVVieTVLSE5YUG5tTF9OeWt4Zmh6UVJFdWI3VmZWMmVtWUktbVdMX1FlOWdCcUF0WjdUZzZ4bFFfUQ?oc=5","date":"2025-12-31","type":"pipeline","source":"BioWorld News","summary":"Blossomhill advancing EGFR, CLK inhibitors with series B extension - BioWorld News","headline":"Blossomhill advancing EGFR, CLK inhibitors with series B extension","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE52WXBFTUIwQm9Fb3ZLa2ZqYXJ2VVhoWGFPUFhRSXpqeE51RFI2Y3hxZC1HN0RuMTd5NjhZVnNycEZEVldvcGw0R3N0aG5LVmhSdnFz?oc=5","date":"2025-12-10","type":"pipeline","source":"FirstWord Pharma","summary":"BlossomHill re-ups with $84M to drive development of macrocyclic cancer assets - FirstWord Pharma","headline":"BlossomHill re-ups with $84M to drive development of macrocyclic cancer assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQTnU1NEpIWEF1TjI1YTVDVERCb3E0TW1odHp2b2F6cTBucmV6eXdZYXh5WEJqRVVkeWRyZDZtZlVpNUNDZjN2U3lEQWxwUzVrYk81SkhiekRUNXl4Qm9ZZGllVVExcll3VnIxY1U5MUVMVEdrc0dIZkJFN2FuV3F3M2hDMm1KUF9BRFFnNFlZMEZTbWRPcDVFUlBUb2hJUVZFdEJDYVVXY3BJNTFET3VzTHhrcFV6Q3o2TV9kc2JjVGpyZw?oc=5","date":"2025-12-10","type":"pipeline","source":"The Pharma Letter","summary":"$84 million Series B extension takes BlossomHill’s fundraising beyond $257 million - The Pharma Letter","headline":"$84 million Series B extension takes BlossomHill’s fundraising beyond $257 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPcWhzQU5YVU9xS0o4VDVhV2hBRlVFQXhoYmJ6NHZKZVpjT2hBOVJZYjdGNno0NTVYZkVSRUJjbjA5SmZMbWF3UkUwX2pxTnpBWDd5NjlWT3dlN0FKazlIcmQxZ3R2T21CTldVZHRlVFFYVVdhMjBZQXpsbHN0cWhzWXg1U3JWWkxTYXB4S3Nn?oc=5","date":"2025-12-10","type":"trial","source":"Endpoints News","summary":"BlossomHill gets another $84M for macrocyclic approach to EGFR - Endpoints News","headline":"BlossomHill gets another $84M for macrocyclic approach to EGFR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxPRzh2WUtYekI3UEg5YjJHNW5XWG4tV0pUTjFtb01NTVpCdU0wNTAycmt6RUNKV0tEZ0d4M3Zvd09VdmtwQllrWjAzZmJxR2xCM2FQakpnYngyOExXbGVQdi1IVVQ0NlBaSGZjTnBoQzRkVGViMXg5b1BzYW5OcVI5clFEakZWOFlYa2RSd1VkcTRyZjA1UnFnNW1OejdKXzJqalhYZC1UM05JOW5wSDlnSnB1VzgzbXY5X2hvUVFhRllPX3NsYVJLa1p0ZGRYbW5UVVVLcXRZV2pWb1VCYi1kNVZncWxFT3B3YVZTdHUyU25weWF1SkQ2V2pvVjJPNVVNNHBzSzRVQ2xCNE5pYnlxNmxYNUVYZERPbFotcU92Tk1XNFJ0S3B0czIyNEt1d2xac0FIOHFvVFhfbkxnNkxFY2lR?oc=5","date":"2025-01-22","type":"trial","source":"Business Wire","summary":"BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer - Business Wire","headline":"BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR-","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPLUk5VWZkZ2V6a1FKQWp4Z3Jhb2JmVVA4NUNwWXpxSHlaRmtJTGpRaFZ1S3l6SDUxRE9mZFNZcjJEdjRsZGVvTjVMbVdCVnlMSlJhZWdlSEtBUmVucVhCelh1RVpRSzVBTkU0YndNcjdBcTk5b3BKUmdQQlJIbnRDMXhVOVA3Y21fQzJiVjFjZFB3UmRYOWtNa0dDNkZFLTdTUHNtWGpyVXphbTJUa3B4SVA2ckVqV1BmSVBvMFk5eFZTV2J0UmFORFlWWWdDY1FfZlY4WnpnMUtGN2NfcUNXRzdzdUExU19KQ040dUVIYndFUGxH?oc=5","date":"2025-01-06","type":"pipeline","source":"Business Wire","summary":"BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire","headline":"BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPME9ibEM5WUxnSlJXYl80ZnVLU05pQUtoaEZZNnd0MVBDZ01JWDJzQlR0UnozSlZzVkJJbXRvdFR0SEFQSTZvYjU4aGtRTExnOEx4ZVp6WjhELVU0dEwtVGJsQUJ0WC1KNGxyVmpmSnUwNm05WG5RajQyX2RDZndHVWpWeER4bnZ4VmNhTmE1Z19NcnlEeUNRd09VOEo0cWJCS213dEtB?oc=5","date":"2024-07-23","type":"earnings","source":"San Diego Business Journal","summary":"BlossomHill Therapeutics Moving to New Headquarters - San Diego Business Journal","headline":"BlossomHill Therapeutics Moving to New Headquarters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPYi1ZcGRZSGFxTlBwbGJWM0RZdlZ2NjBQX0VWX1FMR3BFWHAydFlMbUVYOUdweS1DeXVWOFIwZjRMN3BwUW90ZGY1LUFicDBqd2ZzR2RkV29iOU5KTVJVcWYzWVRnTG9mMGJwT0xiZjhpdGowT1lKVk5uY2FFbGdFOXVLSGpsb3UyZFJTaXJMZkNseGQ1Y3JHV2V1TERxNFV4Y24xR1k4end2VG5JZmxGWlVLTUE0ZUZQMlE?oc=5","date":"2024-05-30","type":"pipeline","source":"Timmerman Report","summary":"Recognizing 11 Asian-American Executives Shaping the Future of Biopharmaceuticals - Timmerman Report","headline":"Recognizing 11 Asian-American Executives Shaping the Future of Biopharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQZXl0NzVsX1BKT3FYaEJIUW5TNTN4QVlCbWJ5bjQ0NXhHUWRUUFV3NVd6MWJSQzJPOExOcFNJd3l2ZnNWMXdEMG9iQkQ0M1VBTHhtd1E2bGZPT0dHY2ZtTjFzZi1sSzBYTnRaY0hNWlc5Xy1SMXpWZ0NPQXJBeFFrWE9GTVNWc2Jxb0FqVHpOamRtcWpQeXdMMVFxc2gtV0NiS3Bscg?oc=5","date":"2024-02-29","type":"pipeline","source":"Fierce Biotech","summary":"With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules - Fierce Biotech","headline":"With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPWVVkMkJrUnlTeUlwMENTTm9mZHNMLXhXNjh2OEdkOHFHRENzMlRrVmlMbUg5N21kQjNPUy11d3Qza3NKOXFteWVFOWRrV2NEa0ZqX3R2dHA4TE0zM1RtYWtGdi1VeFZUS0lGVWNQZ1JDNkNLbzkxX2FLWUVnN2g2VlhQMXBpbVFScU5jNzlDT3YxSnlWeUItNTRB?oc=5","date":"2024-02-29","type":"pipeline","source":"BioPharma Dive","summary":"With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease - BioPharma Dive","headline":"With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQMUZVdGhLY081dmVWUDZiQmNOZHJWeldTS0xTcmM4NFNYTlNCRXVuYVN4cldQRHZoYVExLTQ5X1o2bHBkamFXbTFlTlAwTU9aSW9zdC1wSkZZYUEyMjZfVTZCcjhwODh1cG9MVlB3WTEydTg2MzBzVkxuZmFISnl2akJ5TFNqdk95V0liRnlKNlI0Q2I3TXNBNkQ1clBkOFJxWW1kOHhhTE90RFlWR0ZBV19UWEJqc2N3czlnUGU5aWNIUHFRek5TanBtckF1dHJySmNVZUJKOHRiTzhaNV9teFM1VGo2eGJTQ3BVcHFJSFpPRC1xb2ZlanVLUGNPeXNuTEhtVUtRUQ?oc=5","date":"2024-02-14","type":"pipeline","source":"Business Wire","summary":"BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering - Business Wire","headline":"BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineeri","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}